Panel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial Scale

• Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
• Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
• Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market

Speakers:

Jacob Jeppesen

Chief Scientific Officer & Head of Research & Development

Alveus Therapeutics

Ohad Yogev

Vice President, Discovery

ScionxBio

Martin Hey-Mogensen

Director

Novo Nordisk A/S

Paul Little

Chief Executive Officer

Atrogi